Table 2.
Nuclear factor of activated T cells‐regulated cytokine expression and Tac concentrations among patients with and without subclinical rejection
| 6 weeks post‐Tx | 1 year post‐Tx | |||
|---|---|---|---|---|
| BPAR a | Yes (n = 2) | No (n = 22) | Yes (n = 3)b | No (n = 22) |
| RGE, % | 40.6 (39.7–41.6) | 45.3 (5.65–76.2) | 54.3 (44.8–72.6) | 48.1 (17.2–220) |
| E 0 | 1.46 (0.44–2.48) | 1.98 (0.22–4.99) | 1.65 (1.55–2.18) | 1.80 (0.30–5.64) |
| E 1.5 | 0.60 (0.18–1.03) | 0.73 (0.023–2.52) | 0.841 (0.74–1.58) | 0.98 (0.12–3.45) |
| Tac C 0 , μg l –1 | 5.7 (5–6.3) | 5.9 (3.5–9.3) | 4.3 (4.0–7.2) | 5.6 (3.2–8.3) |
| Tac C 1.5 , μg l –1 | 7.0 (6.5–7.5) | 8.7 (5.0–18.7) | 7.1 (4.7–12.7) | 8.9 (3.8–19.6) |
| Tac doses, mg kg –1 day –1 | 0.060 (0.057–0.063) | 0.048 (0.020–0.107) | 0.049 (0.045–0.089) | 0.042 (0.021–0.117) |
BPAR, biopsy‐proven acute rejection; E0, gene expression before dosing; E1.5, gene expression 1.5 h after dosing; RGE, residual gene expression; Tac C0, predose tacrolimus concentrations; Tac C1.5, tacrolimus concentrations 1.5 h postdose; Tx, transplantation
a
Subclinical biopsy‐proven acute rejection. Gene expression and Tac measurements were performed before the initiation of rejection therapy
b
One patients experienced concurrent viraemia and subclinical rejection